Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BD.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
AY.87 (Delta)NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BE.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.1.9NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.11.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBF.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BZ.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BQ.1.10.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.7.24NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.10NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.44NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BE.1.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.7.4.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.5.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.37NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.2.57NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
CN.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.4.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.54NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.18NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.52NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BL.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BF.11.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.48NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
JQ.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.10.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BL.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-18180US
BA.5.2.23NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BL.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BE.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.9.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.5.6.4NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.2.34NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.17NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.164NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.275NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.258.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.58NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.81NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.419NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.151NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.36.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.10NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.19NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
BA.1.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.11NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.258.7NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.307NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.1.171NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
B.1.177.16NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used